|
Sunlight linked to drug’s effectiveness
International News Network A more detailed analysis showed that the concentrations of drugs such as tacrolimus and sirolimus, which are used to prevent rejection following transplantation, vary throughout the year in a manner that closely reflects changes in the level of vitamin … |
Revlimid Gains New Lymphoma Indication – Monthly Prescribing Reference
iStockAnalystRevlimid Gains New Lymphoma IndicationMonthly Prescribing ReferenceThe new indication approval is based on the results of a Phase 2, multicenter, single-arm, open-label study evaluating lenalidomide in patients (N=134) with MCL who had rec…
Bay Area toddler in recovery after 12-hour organ transplant surgery – Marin Independent Journal
|
Bay Area toddler in recovery after 12-hour organ transplant surgery
Marin Independent Journal Bay Area toddler in recovery after 12-hour organ transplant surgery. By Gary Peterson. Contra Costa Timesmarinij.com. Posted: 06/05/2013 08:41:55 AM PDT. SAN FRANCISCO — The sun wasn’t up at 5 o’clock Wednesday morning, but a new day had … |
We'll go for differential pricing in India: Cadila's Patel – Livemint
Livemint |
We’ll go for differential pricing in India: Cadila’s Patel
Livemint Mumbai: Cadila Healthcare Ltd, which has been working on several new drugs under its dedicated discovery arm, announced its first discovery molecule saroglitazar, a first-of-its-kind medicine to treat dyslipidemia, a crucial condition not addressed in … Zydus’ new drug can control diabetes, cholesterolHindu Business Line Zydus pioneers breakthrough with Lipaglyn to treat diabetic dyslipidemiapharmabiz.com DCGI Approves Launch Of Zydus First NCE ‘Lipaglyn’RTT News |
Indian hospital detains Kenyan over Sh1.8m bill – The Standard Digital News
|
Indian hospital detains Kenyan over Sh1.8m bill
The Standard Digital News However after medical analysis, doctors at the hospital said Wacera’s body was not compatible with a kidney from a family member especially because it had rejected the organ donated by her mother seven years ago after using it for only 11 months … |
Colorado pol facing recall over gun control rails against NRA – Daily Caller
Daily Caller |
Colorado pol facing recall over gun control rails against NRA
Daily Caller Embattled Colorado Senate President John Morse took to Twitter on Tuesday to defend himself against opponents who turned in more than 16,000 signatures to force a recall election for his support of controversial new gun-control laws. Although he’s … |
Biosimilars And Follow-On Biologics: World Market 2013-2023 – The Herald | HeraldOnline.com
|
Biosimilars And Follow-On Biologics: World Market 2013-2023
The Herald | HeraldOnline.com Our study forecasts revenues of prominent biosimilar agents at molecular level: • Rituximab • Infliximab • Trastuzumab. There you discover how high sales can go, to 2023, with individual forecasts. You see what’s happening, understanding trends … |
Second-hand tobacco smoke deadly too: Study – Times of India
Vancouver Sun |
Second-hand tobacco smoke deadly too: Study
Times of India Dr Rana Jugdeep Singh, Technical Advisor (Public Health), International Union Against Tuberculosis and Lung Disease (The Union) said on eve of World Environment Day, that “from one smoke-free jurisdiction, today India has achieved nearly 35 smoke-free … Anti-Smoking Media Campaigns Show Positive Results GloballyAllAfrica.com Do National Smoking Bans Actually Work?TIME Smoking bans must be enforcedThe National Business Recorder all 151 news articles » |
US Food and Drug Administration Approves REVLIMID® (lenalidomide) for the … – Fort Mills Times
|
US Food and Drug Administration Approves REVLIMID® (lenalidomide) for the …
Fort Mills Times … approval was based on the results of MCL-001, a phase II, multi-center, single arm, open label study evaluating lenalidomide in 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or … |
ASCO: Antibody Boosts Chemo in CLL – MedPage Today
ASCO: Antibody Boosts Chemo in CLLMedPage TodayCHICAGO — Adding the novel anti-CD20 agent obinutuzumab to standard chemotherapy for older, sicker patients with chronic lymphocytic leukemia improves outcomes, possibly more so than adding rituximab (Rit…